MLYS · Mineralys Therapeutics, Inc.
$26.90
-0.31 (-1.14%)
At close · Jul 28
Market Cap
$2.24B
Shares
82.50M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$27.21
Open$27.22
Day$27.11–28.11
52W$12.59–47.65
Avg vol 30d1.3M
Short int9.6M · 11.6% float · 9.8d
Short vol52%
Last earningsMay 6, 2026
DataFeb 2023–Jul 2026
Filing10-Q · May 6
Up next
Next earnings call
Aug 5, 2026
Est · unconfirmed
· in 1 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 6, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Neutral
Momentum
Weak
Sentiment
Neutral
Fundamentals
Excellent
Quant / Vol
Very High
Market backdrop
VIX 18.2 · elevated
Equity put/call 0.71
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−15%
below
Price vs 50-day avg
+1%
above
RSI (14)
50
neutral
MACD trend
Negative
52-week position
42%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+3%
trailing
6-month return
−12%
trailing
YTD return
−25%
this year
Relative strength
−18%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $27 › 200d $32 — 200d above 50d
Institutional flow
Distributing
23 of 216 funds reported for Jun 30 · net -246.4K sh shares · +1 new
Insider flow
Distributing
Net -$870.3K over 90 days · 100% sells
Short interest
Falling
11.58% of float · ▼ -13.9% MoM · 9.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
216 holders — mid 3-yr range
Squeeze score
72
high risk · 0–100
Fundamentals
EPS growth
+37%
Y/Y
Balance sheet
$172.9M
net cash
Quant / Vol
risk profile
Volatility
106%
annualized · 1-yr
Max drawdown
−52%
past year
ATR
4.8%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−15%
Bearish
Price vs 50-day avg
+1%
Bullish
RSI (14)
50
Neutral
MACD trend
Negative
Bearish
52-week position
42%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $27 › 200d $32 — 200d above 50d
Institutional flow
Distributing
23 of 216 funds reported for Jun 30 · net -246.4K sh shares · +1 new
Insider flow
Distributing
Net -$870.3K over 90 days · 100% sells
Short interest
Falling
11.58% of float · ▼ -13.9% MoM · 9.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
216 holders — mid 3-yr range
Price context
position in its 52-week range
52-wk low $13
Now $27 · 42%
52-wk high $48
vs 200-day avg -15%
vs 50-day avg +1%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
MLYS
this stock
Mineralys Therapeutics, Inc.
|
$2.24B | -25.0% | — | — | 11.6% |
|
ONC
BeOne Medicines Ltd.
|
$471.01B | +7.3% | +22179.2% | 958.5 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$121.57B | +8.2% | +46.2% | 28.4 | 2.0% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$69.95B | -9.8% | +20.8% | 16.3 | 3.3% |
|
ARGX
Argenx SE
|
$54.57B | +3.7% | — | — | 2.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| MLYS | +0.4% | +3.3% | -11.9% | +0.9% | -25.0% |
| SPY | -0.4% | +1.4% | +6.3% | -1.0% | +8.4% |
| vs SPY | +0.8% | +1.9% | -18.2% | +1.9% | -33.4% |
Key facts
CIK
1933414
CUSIP
603170101
13F (30d)
20 filings
20 filers
Visit website
Investor relations